Plant Name: Plinia cauliflora
Taxonomic Information:
Plant ID: NPO21322
Plant Latin Name: Plinia cauliflora
Taxonomy Genus: Plinia
Taxonomy Family: Myrtaceae
Plant External Links:
NCBI TaxonomyDB:
375264
Plant-of-the-World-Online:
n.a.
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPR35; | |
| RECQL; TDP1; HPGD; AKR1B1; HSD17B2; APEX1; POLB; | |
| TEK; MET; KDR; NUAK1; EGFR; SRC; INSR; IGF1R; CSNK2A1; | |
| CA12; CA7; | |
| TYR; | |
| AHR; | |
| SLC22A6; SLCO1B3; | |
| SMAD3; HSPA1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
| Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0060089; molecular transducer activity | GO:0004714; transmembrane receptor protein tyrosine kinase activity | 3.826E-10 | 2.083E-06 | EGFR, IGF1R, INSR, KDR, MET, TEK |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 7.787E-09 | 1.541E-05 | EGFR, IGF1R, INSR, KDR, SRC |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.556E-08 | 4.076E-05 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 2.540E-07 | 1.620E-04 | EGFR, INSR, KDR |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 3.261E-07 | 1.732E-04 | AKR1B1, APEX1, CSNK2A1, CYP1A2, EGFR, HPGD, INSR, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.625E-07 | 1.865E-04 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.849E-07 | 2.497E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.235E-06 | 4.137E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4, SRC |
| MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.333E-06 | 4.399E-04 | EGFR, IGF1R, INSR, KDR, TEK |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 2.176E-06 | 6.404E-04 | APEX1, POLB |
| BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 2.869E-06 | 8.041E-04 | AKR1B1, CSNK2A1, EGFR, HSPA1A, IGF1R, KDR, SMAD3, SRC, TEK |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.880E-06 | 8.041E-04 | EGFR, INSR, MET, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.974E-06 | 1.055E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 4.793E-06 | 1.200E-03 | CSNK2A1, EGFR, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, RECQL, SRC, TEK |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.281E-06 | 1.307E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 6.523E-06 | 1.439E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0007169; transmembrane receptor protein tyrosine kinase signaling pathway | 7.015E-06 | 1.489E-03 | EGFR, IGF1R, INSR, KDR, MET, SRC, TEK |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 7.830E-06 | 1.579E-03 | CSNK2A1, CYP1A1, CYP1A2, EGFR, HPGD, HSD17B2, SRC, TYR |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 7.722E-06 | 1.579E-03 | EGFR, HPGD, SLC22A6, SLCO1B3, TEK |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 1.014E-05 | 1.989E-03 | AKR1B1, CYP1A1, CYP1A2, CYP1B1, CYP3A4, EGFR, HSPA1A |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.303E-05 | 2.365E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.303E-05 | 2.365E-03 | CYP1A2, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 1.328E-05 | 2.373E-03 | AKR1B1, APEX1, IGF1R, INSR, SRC |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.466E-05 | 2.573E-03 | AHR, CSNK2A1, KDR |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.170E-05 | 3.425E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 2.918E-05 | 4.352E-03 | EGFR, INSR, KDR, SMAD3, SRC |
| BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 3.121E-05 | 4.531E-03 | EGFR, INSR, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.252E-05 | 4.569E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.252E-05 | 4.569E-03 | CYP1A2, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 4.549E-05 | 5.793E-03 | CYP1A2, CYP3A4 |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 4.549E-05 | 5.793E-03 | EGFR, POLB |
| BP | GO:0065007; biological regulation | GO:0048878; chemical homeostasis | 5.535E-05 | 6.848E-03 | AKR1B1, CA12, CA7, EGFR, GPR35, INSR, MET, SMAD3 |
| BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 6.060E-05 | 7.455E-03 | CYP1A1, CYP1A2 |
| BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 7.574E-05 | 8.819E-03 | EGFR, IGF1R, INSR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.038E-11 | 1.121E-09 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 9.024E-09 | 4.873E-07 | INSR, HSD17B2, CYP1A1, CYP1B1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.688E-08 | 5.227E-07 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 6.892E-08 | 1.489E-06 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.936E-08 | 5.227E-07 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 7.641E-07 | 1.375E-05 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 8.019E-06 | 9.623E-05 | INSR, KDR, TEK, MET, EGFR, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.620E-06 | 5.585E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.988E-06 | 9.806E-05 | SRC, KDR, MET, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 9.752E-06 | 9.806E-05 | SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.765E-06 | 7.783E-05 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.427E-05 | 1.284E-04 | INSR, TEK, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 3.902E-05 | 3.010E-04 | SMAD3, INSR, EGFR, IGF1R |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.612E-05 | 2.170E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 1.076E-04 | 7.607E-04 | INSR, HSPA1A, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.289E-04 | 8.191E-04 | SRC, MET, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.466E-04 | 8.797E-04 | MET, EGFR, IGF1R |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.127E-04 | 7.607E-04 | CYP1A2, CYP1A1, CYP3A4 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.915E-04 | 2.114E-03 | SRC, EGFR, HSPA1A |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 2.205E-03 | 9.924E-03 | HPGD, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 1.607E-03 | 7.547E-03 | SRC, EGFR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 8.044E-04 | 4.137E-03 | CYP1A2, CYP3A4 |
| 09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 1.042E-03 | 5.117E-03 | POLB, APEX1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.724E-04 | 1.548E-03 | CA12, CA7 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; TYR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; SRC; |
| C00-D49: Neoplasms | Breast cancer | C50 | IGF1R; KDR; INSR; EGFR; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| NA: NA | HIV infections | NA | AHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
| C00-D49: Neoplasms | Prostate cancer | C61 | EGFR; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | INSR; EGFR; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | IGF1R; INSR; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | INSR; |
| C00-D49: Neoplasms | AML | NA | KDR; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; IGF1R; KDR; TEK; EGFR; SRC; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; SRC; |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| C00-D49: Neoplasms | Cancer | C00-C96 | MET; IGF1R; KDR; CSNK2A1; TEK; EGFR; SRC; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
